GlassScriptPhysician profile
Rita Digrazia Page
NPI 1851788236
$3,278.52
in general payments reported to CMS, 2019-2025
24 companies · $1,049 in 2025
The $1,049 reported for 2025 was more than what 78% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $147 · 2020: $160 · 2021: $143 · 2022: $525 · 2023: $611 · 2024: $644 · 2025: $1,049.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,303.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $981.60 | 2019-2025 | Clareon Panoptix Pro, Clareon, Argos |
| Astellas Pharma US INC | $327.87 | 2023-2025 | Izervay |
| Tarsus Pharmaceuticals, INC. | $215.61 | 2024-2025 | Xdemvy |
| Sight Sciences, INC. | $204.96 | 2024-2025 | Omni Surgical System, Sion Surgical Instrument |
| Horizon Therapeutics Plc | $197.77 | 2022-2023 | Tepezza |
| Novartis Pharmaceuticals Corporation | $187.05 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $183.20 | 2021-2025 | |
| Nova Eye, INC. | $156.90 | 2025 | |
| Biotissue Holdings INC. | $122.09 | 2020-2024 | |
| Allergan, INC. | $109.95 | 2020-2022 | |
| Glaukos Corporation | $94.85 | 2024-2025 | Radius, Idosetr |
| Mallinckrodt Hospital Products INC. | $88.31 | 2021-2024 | Acthar |
| Aerie Pharmaceuticals, INC. | $59.29 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $46.02 | 2020 | |
| Bausch & Lomb Americas INC. | $44.59 | 2025 | Envista Envy Iol, Miebo, Xiidra |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $42.22 | 2024-2025 | Oxervate |
| Abbvie INC. | $41.69 | 2022 | |
| Amgen INC. | $39.04 | 2025 | Tepezza |
| Ocular Therapeutix, INC. | $32.83 | 2024-2025 | Dextenza |
| Rxsight INC | $32.15 | 2022 | |
| Oyster Point Pharma, INC. | $20.31 | 2022 | |
| Thea Pharma INC. | $17.75 | 2023 | Iyuzeh |
| Kala Pharmaceuticals, INC. | $17.24 | 2021 | |
| New World Medical,INC. | $15.23 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rita Page listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.